Articles
| Open Access |
DOI: Generative AI In Life Sciences: Unlocking Operational Value Across the Product Lifecycle
Efim Iuresku , Engagement Manager, Strategic Consulting Firm New York City, USAAbstract
The development and commercialization of pharmaceutical and MedTech products represent one of the most complex and resource-intensive endeavors in the modern economy. The process involves long timelines, high attrition rates, and the integration of vast volumes of structured and unstructured data. Generative artificial intelligence (GenAI) has emerged as a transformative tool capable of enhancing efficiency, accelerating scientific discovery, and streamlining operations across the life sciences value chain - from early research to clinical development, manufacturing, medical affairs, and commercialization.
A synthesis of current literature, real-world implementations, and industry benchmarks was conducted to evaluate high-impact application areas of GenAI in life sciences. Documented use cases from biopharmaceutical and MedTech organizations illustrate the deployment of GenAI in target identification, de novo molecule generation, trial protocol design, medical writing automation, manufacturing deviation analysis, medical engagement support, and omnichannel content generation.
Estimates indicate that GenAI could unlock between $60 billion and $110 billion in annual value across the pharmaceutical industry. The greatest economic potential lies in commercial functions, followed by research and clinical development. Early adopters - including Pfizer, Novartis, AstraZeneca, and Novo Nordisk - have reported productivity improvements ranging from 20% to 60% in pilot programs focused on regulatory documentation, manufacturing quality, and HCP engagement.
Despite these benefits, large-scale adoption remains constrained by several challenges. Key barriers include hallucination risks in language models, regulatory ambiguity, limitations in technical infrastructure and data quality, and resistance to organizational change. Addressing these constraints will be critical to ensuring the safe, compliant, and impactful integration of GenAI technologies into life sciences workflows.
Keywords
Generative AI, Life sciences, Pharmaceutical operations, Pharma digital transformation
References
McKinsey & Company. (2024). Generative AI in the pharmaceutical industry: Moving from hype to reality; https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality
U.S. Food & Drug Administration. (2024). Using Artificial Intelligence & Machine Learning in the Development of Drug and Biological Products; https://www.fda.gov/media/167973/download
McKinsey & Company. (2023). Simplification for success: Rewiring the biopharma operating model; https://www.mckinsey.com/industries/life-sciences/our-insights/simplification-for-success-rewiring-the-biopharma-operating-model
Zheng, Y., Koh, H. Y., Yang, M., Li, L., May, L. T., Webb, G. I., Pan, S., & Church, G. (2024). Large language models in drug discovery and development: From disease mechanisms to clinical trials. arXiv. https://arxiv.org/abs/2409.04481
McKinsey & Company. (2024). Faster, smarter trials: Modernizing biopharma’s R&D IT applications; https://www.mckinsey.com/industries/life-sciences/our-insights/faster-smarter-trials-modernizing-biopharmas-r-and-d-it-applications
Nature Reviews Drug Discovery. (2023). Generative AI and the Future of Early Drug Discovery; https://www.nature.com/articles/s41573-023-00388-w
McKinsey & Company. (2024). Generative AI in healthcare: Current trends and future outlook; https://www.mckinsey.com/industries/healthcare/our-insights/generative-ai-in-healthcare-current-trends-and-future-outlook
European Medicines Agency. (2024). Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle; https://www.ema.europa.eu
MIT Technology Review. (2024). AI hallucinations are poisoning medical science - how can we fix it; https://www.technologyreview.com
Insilico Medicine. (2024). AI-powered drug discovery platform Chemistry42; https://insilico.com/chemistry42
Pfizer. (2023). Innovation Through GenAI in Clinical Development; https://www.pfizer.com
Novartis. (2024). Reimagining Manufacturing with AI-Driven Digital Twins; https://www.novartis.com
AstraZeneca. (2023). AI in Medical Affairs: Driving Real-Time HCP Engagement; https://www.astrazeneca.com
Novo Nordisk. (2023). Omnichannel Engagement with GenAI in Diabetes; https://www.novonordisk.com
Article Statistics
Copyright License
Copyright (c) 2025 Efim Iuresku
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.